Blood News and Research

RSS

Regadenoson drug is safe for heart transplant patients: Study

The drug regadenoson is safe and poses fewer side effects than the conventional medication used during a cardiac nuclear stress test of heart transplant patients, according to a Henry Ford Hospital study.

15 Mar 2010

Researchers develop Intermountain Risk Score tool to assess patients' health

Researchers from the Heart Institute at Intermountain Medical Center in Murray, Utah, have devised a better way to determine an individual's risk for problems, such as heart attack and heart failure, according to a new study.

15 Mar 2010

Data shows increased risk of heart attack, stroke for patients having high blood pressure

For patients with diabetes and heart disease, less isn't always more - at least when it comes to blood pressure.

15 Mar 2010

Supplementing vitamin D in people with low levels may have different effects based on patient race

Vitamin D is quickly becoming the "go-to" remedy for treating a wide range of illnesses, from osteoporosis to atherosclerosis. However, new evidence from a Wake Forest University School of Medicine study suggests that supplementing vitamin D in those with low levels may have different effects based on patient race and, in black individuals, the supplement could actually do harm.

15 Mar 2010

XOMA 052 reduces adverse consequences that lead to development of congestive heart failure

XOMA Ltd., a leader in the discovery and development of antibody therapeutics, announced results demonstrating that a murine equivalent of XOMA 052, its novel, high-affinity antibody to interleukin-1 beta (IL-1 beta), significantly reduced adverse consequences that usually lead to the development of congestive heart failure in a mouse model of acute myocardial infarction (heart attack).

15 Mar 2010

Discovery may yield new strategies for blocking malaria transmission

Scientists studying the Anopheles gambiae mosquito - the main vector of malaria - have found that when the mosquito takes a blood meal, that act triggers two enzymes to form a network of crisscrossing proteins around the ingested blood.

15 Mar 2010

Challenges in treating AML and recent updates to NCCN Guidelines presented at NCCN Annual Conference

Using risk stratification to assist in treatment selection was just one of the focal points at a recent presentation of the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines™) for Acute Myeloid Leukemia (AML) at the NCCN 15th Annual Conference.

15 Mar 2010

New PEGylated Polylysine dendrimers: Benefits patients with cancer, HIV and lymphatic conditions

Monash Institute of Pharmaceutical Science researchers, in collaboration with the biotechnology company Starpharma Holdings Ltd have developed a new method to deliver medications that may benefit thousands of patients with particular types of cancer, HIV and lymphatic conditions world-wide.

15 Mar 2010

Nanoparticles provide a targeted version of photothermal therapy for cancer

In a lecture he delivered in 1906, the German physician Paul Ehrlich coined the term Zuberkugel, or "magic bullet," as shorthand for a highly targeted medical treatment.

15 Mar 2010

Combination therapy does not reduce cardiovascular risk in type 2 diabetes patients

Lowering blood pressure to normal levels - below currently recommended levels - did not significantly reduce the combined risk of fatal or nonfatal cardiovascular disease events in adults with type 2 diabetes who were at especially high risk for cardiovascular disease events, according to new results from the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial.

15 Mar 2010

Obese type 2 diabetics carry mitochondrial proteins that reduce response to physical exercise

Diet and aerobic exercise are highly effective for the treatment of type 2 diabetes, but not for obese subjects that have developed the disease when very young. A study at the Institute for Research in Biomedicine and Trinity College in Dublin demonstrates that obese subjects between 18 and 25 years of age carry mitochondrial proteins and genes that work abnormally and that these anomalies contribute to generating insulin resistance and a reduced response to physical exercise.

15 Mar 2010

Medafor, Magle Life Sciences of Sweden sign long-term raw material supply agreement

Medafor Inc. announced today that it has signed a long-term raw material supply agreement with Magle Life Sciences of Sweden, the supplier of the key powder component for Medafor’s patented MPH(R) (Microporous Polysaccharide Hemosphere) surgical product, which is used by surgeons to control bleeding in complex surgical operations.

15 Mar 2010

Ligand Pharmaceuticals: GSK granted marketing authorization from EC for Revolade

Ligand Pharmaceuticals Incorporated today announced that GlaxoSmithKline was granted marketing authorization from the European Commission for Revolade® (eltrombopag) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).

15 Mar 2010

New study finds green tea extract may prevent Alzheimer's disease and dementia

Long known to be beneficial in heart disease, diabetes and some cancers, a new study finds a specific green tea extract may delay or prevent Alzheimer's disease and dementia. A. Holliday & Company's "Teawell 50," is a 50 percent pure extraction of EGCG (epigallocatechin gallate) – a flavonoid which is the most potent of four major catechins in green tea.

15 Mar 2010

New hydrosurgery system may help manage excessive bleeding during surgery

Carnegie Mellon University's Matt Oberdier is developing a new hydrosurgery system to help physicians better manage excessive bleeding during surgery.

15 Mar 2010

FDA warns patients and physicians about the efficacy of Plavix treatment

The U.S. Food and Drug Administration today added a boxed warning to the anti-blood clotting drug Plavix (clopidogrel), alerting patients and health care professionals that the drug can be less effective in people who cannot metabolize the drug to convert it to its active form.

15 Mar 2010

ARS study underlines the importance of vitamin D and its ability to help body utilize calcium

Increasing calcium intake is a common--yet not always successful--strategy for reducing bone fractures. But a study supported in part by the Agricultural Research Service (ARS) underscores the importance of vitamin D and its ability to help the body utilize calcium. The study also may explain why increasing calcium alone isn't always successful in dealing with this problem.

12 Mar 2010

Telemonitoring may reduce mortality of heart failure patients by 20%

Telemonitoring may reduce the mortality of patients with heart failure by 20%. Silke Schmidt et al. present their study results in the current issue of Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107[8]131-8).

12 Mar 2010

XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced the initiation of a Phase 2 clinical trial of XOMA 052, its antibody to interleukin-1 beta (IL-1 beta), in Type 1 diabetes patients. Funding for the trial is being provided by the Juvenile Diabetes Research Foundation International, the largest patient advocacy organization of Type 1 diabetes research worldwide.

12 Mar 2010

Vertos Medical announces positive results from IRB I Patient Outcomes Trial of 'mild' for LSS

Medical device company Vertos Medical Inc. has announced the release of positive results from its U.S. IRB I Patient Outcomes Trial, a prospective, investigational review board-approved, 75-patient study of mild for the treatment of lumbar spinal stenosis (LSS). Six-week clinical data have shown that patients treated with mild experience statistically and clinically significant improvement in both pain and functional ability. The data also confirmed mild’s safety, with no reports of patient complications related to the procedure or the devices.

12 Mar 2010

Blood News and Research

Regadenoson drug is safe for heart transplant patients: Study

Researchers develop Intermountain Risk Score tool to assess patients' health

Data shows increased risk of heart attack, stroke for patients having high blood pressure

Supplementing vitamin D in people with low levels may have different effects based on patient race

XOMA 052 reduces adverse consequences that lead to development of congestive heart failure

Discovery may yield new strategies for blocking malaria transmission

Challenges in treating AML and recent updates to NCCN Guidelines presented at NCCN Annual Conference

New PEGylated Polylysine dendrimers: Benefits patients with cancer, HIV and lymphatic conditions

Nanoparticles provide a targeted version of photothermal therapy for cancer

Combination therapy does not reduce cardiovascular risk in type 2 diabetes patients

Obese type 2 diabetics carry mitochondrial proteins that reduce response to physical exercise

Medafor, Magle Life Sciences of Sweden sign long-term raw material supply agreement

Ligand Pharmaceuticals: GSK granted marketing authorization from EC for Revolade

New study finds green tea extract may prevent Alzheimer's disease and dementia

New hydrosurgery system may help manage excessive bleeding during surgery

FDA warns patients and physicians about the efficacy of Plavix treatment

ARS study underlines the importance of vitamin D and its ability to help body utilize calcium

Telemonitoring may reduce mortality of heart failure patients by 20%

XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients

Vertos Medical announces positive results from IRB I Patient Outcomes Trial of 'mild' for LSS

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News